Literature DB >> 15566933

Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure.

Jamshid Alaeddini1, Patricia A Uber, Myung H Park, Robert L Scott, Hector O Ventura, Mandeep R Mehra.   

Abstract

This study sought to evaluate the utility of sildenafil in assessing pulmonary artery reactivity in left-sided cardiac failure and secondary pulmonary hypertension (PH). Fourteen consecutive patients with heart failure were studied, with oral doses of either sildenafil 25 mg (n = 8) or 50 mg (n = 6) every 8 hours for </=3 doses, and invasive serial hemodynamic measurements were performed. Thirteen patients (93%) demonstrated >20% decreases in pulmonary artery pressures. There was also a 20% reduction of the pulmonary vascular resistance/systemic vascular resistance ratio, indicating relative pulmonary artery selectivity. Compared with sildenafil 25 mg, sildenafil 50 mg demonstrated greater reductions of pulmonary pressures. Oral sildenafil is safe and effective for the evaluation of PH reactivity in heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15566933     DOI: 10.1016/j.amjcard.2004.07.157

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Pulmonary hypertension with left-sided heart disease.

Authors:  Marco Guazzi; Ross Arena
Journal:  Nat Rev Cardiol       Date:  2010-10-05       Impact factor: 32.419

Review 2.  Right ventricular failure: a novel era of targeted therapy.

Authors:  Dipanjan Banerjee; Francois Haddad; Roham T Zamanian; Jayan Nagendran
Journal:  Curr Heart Fail Rep       Date:  2010-12

3.  Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.

Authors:  Gaurav Gulati; E Wilson Grandin; Kevin Kennedy; Fausto Cabezas; David D DeNofrio; Robb Kociol; J Eduardo Rame; Francis D Pagani; James K Kirklin; Robert L Kormos; Jeffrey Teuteberg; Michael Kiernan
Journal:  Circ Heart Fail       Date:  2019-06-11       Impact factor: 8.790

4.  Treatment for pulmonary hypertension of left heart disease.

Authors:  Marco Guazzi; Alessandra Vitelli; Valentina Labate; Ross Arena
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

5.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

6.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06

Review 7.  Right ventricular failure complicating heart failure: pathophysiology, significance, and management strategies.

Authors:  Mobusher Mahmud; Hunter C Champion
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

8.  Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

Authors:  Peter Steele; Geoff Strange; John Wlodarczyk; Brad Dalton; Simon Stewart; Eli Gabbay; Anne Keogh
Journal:  BMC Cardiovasc Disord       Date:  2010-02-22       Impact factor: 2.298

Review 9.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

Review 10.  Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications.

Authors:  Praneet Kumar; Gary S Francis; W H Wilson Tang
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.